NEW YORK, NY / ACCESSWIRE / August 30, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Metagenomi, Inc. ("Metagenomi") (NASDAQ:MGX) concerning possible violations of federal securities laws.
On May 1, 2024, Metagenomi surprisingly announced the "Mutual termination of Moderna Collaboration." Previously, on February 12, 2024, Metagenomi issued its initial public offering of 6.25 million shares in the Company at a price of $15.00 per share. The prospectus annexed to the IPO prominently featured the details and benefits of a Strategic Collaboration and License Agreement Metagenomi entered into with ModernaTX, Inc. in October 2021, which was "focused on advancing new genome editing system for in vivio human therapeutic applications."
Following this news, Metagenomi's stock price fell by $0.87 per share to close at $6.17 per share. To obtain additional information, go to:
https://zlk.com/pslra-1/metagenomi-lawsuit-submission-form?prid=99291&wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP